Published in Neurosurgery on July 01, 2002
Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci (2005) 2.17
Diffuse glioma growth: a guerilla war. Acta Neuropathol (2007) 2.11
Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev (2007) 1.38
Histology-based expression profiling yields novel prognostic markers in human glioblastoma. J Neuropathol Exp Neurol (2005) 1.34
Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity. Cancer Biol Ther (2009) 1.10
Volumetric and MGMT parameters in glioblastoma patients: survival analysis. BMC Cancer (2012) 1.05
Investigation of chromosome 1q reveals differential expression of members of the S100 family in clinical subgroups of intracranial paediatric ependymoma. Br J Cancer (2008) 1.02
Necrosis induction in glioblastoma cells reveals a new "bioswitch" function for the MT1-MMP/G6PT signaling axis in proMMP-2 activation versus cell death decision. Neoplasia (2007) 0.94
Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. Clin Med Insights Oncol (2011) 0.92
Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma. Brain Pathol (2007) 0.87
Imaging hypoxia in gliomas. Br J Radiol (2011) 0.87
Bcl-2 promotes malignant progression in a PDGF-B-dependent murine model of oligodendroglioma. Int J Cancer (2011) 0.86
The lectin concanavalin-A signals MT1-MMP catalytic independent induction of COX-2 through an IKKgamma/NF-kappaB-dependent pathway. J Cell Commun Signal (2010) 0.84
Vibrational Imaging of Glucose Uptake Activity in Live Cells and Tissues by Stimulated Raman Scattering. Angew Chem Int Ed Engl (2015) 0.83
18F-fluorothymidine-pet imaging of glioblastoma multiforme: effects of radiation therapy on radiotracer uptake and molecular biomarker patterns. ScientificWorldJournal (2013) 0.82
Brain tumor classification using the diffusion tensor image segmentation (D-SEG) technique. Neuro Oncol (2014) 0.82
Innovative Therapies against Human Glioblastoma Multiforme. ISRN Oncol (2011) 0.81
The role of AEG-1/MTDH/LYRIC in the pathogenesis of central nervous system disease. Adv Cancer Res (2013) 0.80
A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors. Dis Model Mech (2014) 0.80
Distribution of polymer nanoparticles by convection-enhanced delivery to brain tumors. J Control Release (2016) 0.79
Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment. J Neuropathol Exp Neurol (2015) 0.78
Necrotic cells influence migration and invasion of glioblastoma via NF-κB/AP-1-mediated IL-8 regulation. Sci Rep (2016) 0.78
A combinatorial radiographic phenotype may stratify patient survival and be associated with invasion and proliferation characteristics in glioblastoma. J Neurosurg (2015) 0.76
Image-driven modeling of the proliferation and necrosis of glioblastoma multiforme. Theor Biol Med Model (2017) 0.75
An intrinsic DFF40/CAD endonuclease deficiency impairs oligonucleosomal DNA hydrolysis during caspase-dependent cell death: a common trait in human glioblastoma cells. Neuro Oncol (2016) 0.75
Combined local blood-brain barrier opening and systemic methotrexate for the treatment of brain tumors. J Cereb Blood Flow Metab (2015) 0.75
A statistical model describing combined irreversible electroporation and electroporation-induced blood-brain barrier disruption. Radiol Oncol (2016) 0.75
Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery (2003) 0.75
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol (2009) 9.90
Bioavailability of curcumin: problems and promises. Mol Pharm (2007) 8.72
The role of autophagy in cancer development and response to therapy. Nat Rev Cancer (2005) 8.18
Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 7.31
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res (2005) 5.17
Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol (2007) 5.13
Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res (2008) 4.29
Nuclear factor-kappaB: its role in health and disease. J Mol Med (Berl) (2004) 4.01
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res (2004) 3.63
Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett (2008) 3.61
FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell (2011) 3.58
FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res (2006) 3.28
Cancer is a preventable disease that requires major lifestyle changes. Pharm Res (2008) 3.28
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett (2008) 3.14
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res (2005) 3.07
Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol (2008) 2.95
Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J (2009) 2.89
Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene (2004) 2.82
Retracted Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells. Cancer Res (2013) 2.75
Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol (2010) 2.71
Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol (2007) 2.70
Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res (2006) 2.70
Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol (2003) 2.63
Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol (2005) 2.62
Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev (2010) 2.57
Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta (2010) 2.55
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev (2011) 2.48
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res (2002) 2.45
Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol (2003) 2.44
"Spicing up" of the immune system by curcumin. J Clin Immunol (2007) 2.43
Curcumin: getting back to the roots. Ann N Y Acad Sci (2005) 2.42
Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J (2012) 2.42
Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol (2002) 2.27
Retracted Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res (2010) 2.24
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst (2007) 2.23
Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol (2003) 2.22
Reactive oxygen intermediates in TNF signaling. Mol Immunol (2002) 2.20
Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood) (2008) 2.19
Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res (2011) 2.15
Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res (2008) 2.15
Retracted Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol (2009) 2.12
Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle (2008) 2.10
Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal (2012) 2.05
Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. J Biol Chem (2003) 2.05
Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci (2005) 2.05
NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem (2009) 2.03
Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest (2004) 2.02
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol (2007) 2.01
FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res (2008) 2.01
Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther (2010) 2.00
Role of curcumin in cancer therapy. Curr Probl Cancer (2007) 2.00
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol (2010) 1.99
Cancer prevention with natural compounds. Semin Oncol (2010) 1.98
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res (2007) 1.98
Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res (2003) 1.96
Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol (2005) 1.94
A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res (2006) 1.92
Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res (2006) 1.91
TNF: a master switch for inflammation to cancer. Front Biosci (2008) 1.91
Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem (2003) 1.91
Anticancer potential of silymarin: from bench to bed side. Anticancer Res (2007) 1.91
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res (2004) 1.90
Role of chemopreventive agents in cancer therapy. Cancer Lett (2004) 1.88
Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res (2008) 1.88
Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst (2003) 1.86
Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Clinical article. J Neurosurg (2010) 1.85
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res (2006) 1.82
A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res (2008) 1.80
Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis (2002) 1.79
Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res (2002) 1.78
Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis (2007) 1.78
Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol (2014) 1.77
The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest (2013) 1.76
Obtaining reliable information from minute amounts of RNA using cDNA microarrays. BMC Genomics (2002) 1.75
Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci (2013) 1.72
Retracted Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake. Biochem Pharmacol (2010) 1.72
Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol (2012) 1.72